Theisen Frank M, Hinney Anke, Brömel Torsten, Heinzel-Gutenbrunner Monika, Martin Matthias, Krieg Jürgen-Christian, Remschmidt Helmut, Hebebrand Johannes
Clinical Research Group, Department of Child and Adolescent Psychiatry, University of Marburg, Germany.
Psychiatr Genet. 2004 Sep;14(3):139-42. doi: 10.1097/00041444-200409000-00003.
Weight gain is a major side effect of treatment with clozapine and other antipsychotics. Recent studies suggest an important role of the serotonin type 2C receptor gene (5-HT2CR) in antipsychotic-induced weight gain. However, investigations pertaining to a possible association between a -759C/T polymorphism (C allele) of the 5-HT2CR and weight gain induced by clozapine and/or other antipsychotics have yielded inconsistent results. We investigated the -759C/T polymorphism of the 5-HT2CR in relation to clozapine-induced change in body mass index (BMI) (kg/m) in 97 German patients with schizophrenia and found no association between the -759C allele and weight gain after 12 weeks of clozapine treatment. In addition, confounding effects of initial BMI, age, sex and duration of illness on change in BMI could not be detected by multiple linear regression analysis. Our data do not support an involvement of the -759C/T polymorphism of the 5-HT2CR in clozapine-induced weight gain in German patients with schizophrenia. Further pharmacogenetic studies pertaining to antipsychotic-induced weight gain are warranted.
体重增加是使用氯氮平和其他抗精神病药物治疗的主要副作用。最近的研究表明，5-羟色胺2C型受体基因（5-HT2CR）在抗精神病药物引起的体重增加中起重要作用。然而，关于5-HT2CR的-759C/T多态性（C等位基因）与氯氮平和/或其他抗精神病药物引起的体重增加之间可能存在的关联的调查结果并不一致。我们在97名德国精神分裂症患者中研究了5-HT2CR的-759C/T多态性与氯氮平引起的体重指数（BMI，kg/m）变化的关系，发现-759C等位基因与氯氮平治疗12周后的体重增加之间没有关联。此外，通过多元线性回归分析未检测到初始BMI、年龄、性别和病程对BMI变化的混杂影响。我们的数据不支持5-HT2CR的-759C/T多态性参与德国精神分裂症患者氯氮平引起的体重增加。有必要进行更多关于抗精神病药物引起体重增加的药物遗传学研究。
